Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)
July 06, 2023 08:15 ET
|
Biodexa Pharmaceuticals PLC
6 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG) Biodexa Pharmaceuticals PLC...
IBT offentliggör utfall i företrädesemissionen
July 04, 2023 02:30 ET
|
Infant Bacterial Therapeutics AB
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SCHWEIZ, SINGAPORE, SYDAFRIKA,...
IBT announces outcome of its rights issue
July 04, 2023 02:30 ET
|
Infant Bacterial Therapeutics AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND,...
Ytterligare Infant Bacterial Therapeutics produkt beviljas “orphan drug” status av FDA
July 03, 2023 10:39 ET
|
Infant Bacterial Therapeutics AB
FDA har beviljat särläkemedelsstatus för IBT:s produkt IBP-1016 för gastroschisis. Barn som drabbas av gastroschisis har ökade risker av tillväxthämning, sepsis och NEC vilket i sin tur...
Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation
July 03, 2023 10:39 ET
|
Infant Bacterial Therapeutics AB
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis. Infants suffering from gastroschisis suffer from risks of growth retardation, sepsis and NEC which leads to...
Rare Diseases Market Report 2023-2033: Home-based Care Anticipated to Offer Lucrative Growth Prospects
June 26, 2023 04:18 ET
|
Research and Markets
Dublin, June 26, 2023 (GLOBE NEWSWIRE) -- The "Rare Diseases Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the Rare Diseases...
ADR Ratio Change
June 22, 2023 16:15 ET
|
Biodexa Pharmaceuticals PLC
22 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of...
Futilitetsanalysen för IBTs Connection Study positiv
June 21, 2023 11:20 ET
|
Infant Bacterial Therapeutics AB
“IBT har tidigare idag meddelat att Data Monitoring Committee (DMC) utfört den planerade säkerhetsgenomgången av studiedata av 1403 för tidigt födda barn. Vi nu även erhållit resultat från den...
The futility analysis for IBT’s Connection Study positive
June 21, 2023 11:20 ET
|
Infant Bacterial Therapeutics AB
“IBT announced earlier today that the Data Monitoring Committee (DMC) has performed the planned safety analysis of the study data of 1,403 babies. We have now also received results from the...
IBT continues to recruit prematurely born infants to The Connection Study following a planned safety analysis.
June 21, 2023 02:55 ET
|
Infant Bacterial Therapeutics AB
In accordance with the study protocol, the independent Data Monitoring Committee (DMC) has performed the final planned safety analysis of Infant Bacterial Therapeutics AB (IBT) drug candidate...